Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (2808)	11/15/1997 2:31:00 PM
From: JOHN W.	Respond to of 6136

Subject: Re: value is obvious Date: Sat, Nov 15, 1997 12:51 EST From: Taurus8266 Message-id: <19971115175100.MAA21553@ladder01.news.aol.com> Ah, more hidden gems with blockbuster potential in the pipe...gem #1...have you noticed in the annual report that AGPH is near ready to progress a NPY antagonist to clinical trials (p7). Watch out Pfizer. NPY is the most potent peptide known at affect feeding (PNAS,v88,p10931)..we're talking the multibillion dollar obesity field which is now wide open to competition with the AHP disaster. This work is a nice compliment to Roche's work with lipoprotein lipase and the leptin receptor...no need to worry about Ligand competition here...and what less would you expect from a putative Roche subsidiary.